Case 2: Features of Genotypic and Phenotypic Resistance Assays

Case-Based Modules
Initial Evaluation
Dermatologic Manifestations
Oral Manifestations
OIs: Prophylaxis
OIs: Treatment
Antiretroviral Rx
Antiretroviral Rx: Resistance
Antiretroviral Rx: Adverse Effects
Drug-Drug Interactions
Postexposure Prophylaxis
Perinatal Transmission
Special Populations
Prevention for Positives
Challenging Unknowns
Interactive Tutorials
This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

Home
About This Site
Free CME
AETC NRC
Resources
Feedback
Site Map
Authors

Question | Discussion | References | CME Credit

You answered:

	The genotypic assay detects resistance in greater than 98% of minority populations of HIV that exist within an individual.

This answer is incorrect. Both genotypic and phenotypic resistance assays analyze the majority populations of HIV within an individual and thus may fail to detect resistance in many of the minority populations of HIV.

	Compared with the phenotypic assay, the genotypic assay is more expensive and has a longer turnaround time.
	The M184V mutation notation refers to the replacement of the amino acid methionine (M) by valine (V) at amino acid position 184.
	When a patient is undergoing a change in antiretroviral therapy because of virologic failure, genotypic resistance testing does not provide any benefit in improving virologic responses.

[Back to Case 2 Question | Go to Correct Answer]

Antiretroviral Rx: Resistance

Case 2: Features of Genotypic and Phenotypic Resistance Assays